[go: up one dir, main page]

MX2007009050A - Anti a beta antibody formulation. - Google Patents

Anti a beta antibody formulation.

Info

Publication number
MX2007009050A
MX2007009050A MX2007009050A MX2007009050A MX2007009050A MX 2007009050 A MX2007009050 A MX 2007009050A MX 2007009050 A MX2007009050 A MX 2007009050A MX 2007009050 A MX2007009050 A MX 2007009050A MX 2007009050 A MX2007009050 A MX 2007009050A
Authority
MX
Mexico
Prior art keywords
formulations
histidine
mannitol
amino acid
molecular weight
Prior art date
Application number
MX2007009050A
Other languages
Spanish (es)
Inventor
Nicholas W Warne
Donna Luisi
Angela Kantor
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of MX2007009050A publication Critical patent/MX2007009050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides formulations for maintaining the stability of ??binding polypeptides, for example, ??antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.
MX2007009050A 2005-01-28 2006-01-27 Anti a beta antibody formulation. MX2007009050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64863105P 2005-01-28 2005-01-28
PCT/US2006/002837 WO2006083689A2 (en) 2005-01-28 2006-01-27 Anti a beta antibody formulation

Publications (1)

Publication Number Publication Date
MX2007009050A true MX2007009050A (en) 2008-04-04

Family

ID=36686080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007009050A MX2007009050A (en) 2005-01-28 2006-01-27 Anti a beta antibody formulation.

Country Status (30)

Country Link
US (2) US7635473B2 (en)
EP (2) EP2392353A1 (en)
JP (1) JP4977625B2 (en)
KR (1) KR101188060B1 (en)
CN (2) CN103768009B (en)
AR (1) AR052198A1 (en)
AU (1) AU2006211184B8 (en)
BR (1) BRPI0607039A2 (en)
CA (1) CA2593122C (en)
DK (1) DK1853310T3 (en)
DO (1) DOP2006000021A (en)
EA (2) EA021507B1 (en)
ES (1) ES2391407T3 (en)
GT (1) GT200600031A (en)
HK (3) HK1108132A1 (en)
IL (1) IL184599A (en)
JO (1) JO2740B1 (en)
MX (1) MX2007009050A (en)
MY (1) MY177052A (en)
NO (1) NO20073305L (en)
NZ (1) NZ556393A (en)
PE (1) PE20060879A1 (en)
PL (1) PL1853310T3 (en)
PT (1) PT1853310E (en)
SI (1) SI1853310T1 (en)
TW (1) TWI398263B (en)
UA (1) UA87549C2 (en)
UY (1) UY29351A1 (en)
WO (1) WO2006083689A2 (en)
ZA (1) ZA200705710B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP2082749A3 (en) * 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7807804B2 (en) * 2004-10-05 2010-10-05 Wyeth Llc Methods and compositions for improving recombinant protein production
ES2434732T3 (en) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Humanized beta-amyloid antibodies for use in improving cognition
ES2396555T3 (en) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Antibodies that recognize beta amyloid peptide
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
PE20061323A1 (en) 2005-04-29 2007-02-09 Rinat Neuroscience Corp ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
BRPI0611599A2 (en) 2005-06-17 2011-02-22 Elan Pharma Int Ltd method for purifying a beta-binding protein and beta-binding protein
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
ES2453941T5 (en) 2005-11-30 2017-05-31 Abbvie Inc. Monoclonal antibodies against beta amyloid protein and uses thereof
KR101591206B1 (en) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. A beta 1-42 specific monoclonal antibodies with therapeutic properties
ES2517420T3 (en) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, procedures and uses
RU2429244C2 (en) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Improved protofibril-selective antibodies and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101553504A (en) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Abeta antibody parenteral formulation
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
PT2182983E (en) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
MX2010012473A (en) 2008-05-23 2011-02-23 Siwa Corp Methods, compositions and apparatuses for facilitating regeneration.
JP2011522842A (en) * 2008-06-12 2011-08-04 アフィリス・アクチェンゲゼルシャフト Compounds for the treatment of symptoms associated with Parkinson's disease
MX2011002372A (en) * 2008-09-10 2011-04-04 Genentech Inc Compositions and methods for the prevention of oxidative degradation of proteins.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MY174760A (en) 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201201227A1 (en) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Biparate-β-beta-binding polypeptides
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
JP6055412B2 (en) * 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー Immunoglobulin stabilization via aqueous formulations with histidine at mildly acidic to neutral pH
JO3400B1 (en) * 2010-09-30 2019-10-20 Ferring Bv Pharmaceutical compound of carbetocin
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
TR201810703T4 (en) * 2011-03-25 2018-08-27 Hoffmann La Roche New protein purification methods.
TWI723339B (en) * 2011-05-02 2021-04-01 美商千禧製藥公司 Formulation for anti-α4β7 antibody
JP6024025B2 (en) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ultrafiltration concentration of allotype-selected antibodies for small volume administration
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
IN2014CN03555A (en) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
RU2714919C2 (en) 2013-08-30 2020-02-21 Такеда Гмбх Gm-csf-neutralizing antibodies for use in treating rheumatoid arthritis or as analgesics
TWI694836B (en) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 Antibody formulation
MX379241B (en) 2014-07-10 2025-03-10 Bioarctic Neuroscience Ab Improved a㟠protofibril binding antibodies
US10584180B2 (en) 2014-09-19 2020-03-10 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
PE20180158A1 (en) 2014-10-24 2018-01-18 Merck Sharp & Dohme COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
WO2016177913A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AR104847A1 (en) 2015-06-17 2017-08-16 Lilly Co Eli FORMULATION OF ANTI-CGRP ANTIBODY
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
IL312251A (en) 2015-10-02 2024-06-01 Hoffmann La Roche Human anti-CD20/human transferrin receptor bispecific antibodies and methods of use
EP3677598B1 (en) 2016-02-19 2022-04-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017181116A1 (en) * 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
BR112019021471A2 (en) 2017-04-13 2020-05-12 Siwa Corporation HUMANIZED MONOCLONAL ANTIBODY OF FINAL PRODUCT OF ADVANCED GLYCUS
BR112019022873A8 (en) 2017-05-02 2023-04-11 Merck Sharp & Dohme FORMULATION, AND, INJECTION VESSEL OR DEVICE.
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
ES2945165T3 (en) * 2017-08-22 2023-06-28 Biogen Ma Inc Pharmaceutical compositions containing anti-amyloid beta antibodies
CA3073286A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
WO2019060062A1 (en) * 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. Methods of reducing particle formation and compositions formed thereby
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
KR20220011697A (en) 2019-05-22 2022-01-28 바이오비에 아이앤씨. Terlipressin Formulation
KR20230039734A (en) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 anti-Aβ antibody
WO2024246085A1 (en) 2023-05-31 2024-12-05 F. Hoffmann-La Roche Ag Therapeutic use of bispecific anti-abeta/tfr antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimeric monoclonal antibody and its production method
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2727112B2 (en) * 1988-04-26 1998-03-11 コニカ株式会社 Stable peroxidase composition and stable antibody composition
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
JP4146512B2 (en) 1991-03-01 2008-09-10 ダイアックス コープ． Small protein
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
JP2966592B2 (en) * 1991-07-20 1999-10-25 萩原 義秀 Stabilized human monoclonal antibody preparation
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ATE216590T1 (en) 1995-02-06 2002-05-15 Genetics Inst DRUG FORMULATIONS FOR IL-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP2002514919A (en) 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド Multivalent and polyclonal libraries
DE69810481T2 (en) 1997-06-13 2003-09-25 Genentech Inc., San Francisco STABILIZED ANTIBODY FORMULATION
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
ES2253839T3 (en) 1997-12-03 2006-06-01 Neuralab, Ltd. SUPPRESSION OF CHANGES RELATED TO AMILOID BETA IN THE DISEASE OF ALZHEIMER.
US20050059591A1 (en) 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US7282570B2 (en) * 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6582945B1 (en) 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
EP1368486A4 (en) 1999-07-15 2009-04-01 Genetics Inst Llc Formulations for il-11
EP3070100B1 (en) 2000-02-24 2021-07-07 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
JP2003516929A (en) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド Prevention and treatment of amyloidogenic diseases
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6916745B2 (en) * 2003-05-20 2005-07-12 Fairchild Semiconductor Corporation Structure and method for forming a trench MOSFET having self-aligned features
DE60229051D1 (en) 2001-04-30 2008-11-06 Lilly Co Eli HUMANIZED ANTIBODIES
ES2318006T3 (en) 2001-04-30 2009-05-01 Eli Lilly And Company HUMANIZED ANTIBODIES RECOGNIZING THE BETA-AMYLOID PEPTIDE.
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (en) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド Stable lyophilized pharmaceutical formulation of IgG antibody
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US20030171556A1 (en) 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
EP1594969B1 (en) 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
KR101157694B1 (en) 2003-12-17 2012-06-20 와이어쓰 엘엘씨 Immunogenic peptide carrier conjugates and methods of producing same
KR101158147B1 (en) 2003-12-17 2012-07-17 와이어쓰 엘엘씨 An immunogenic peptide carrier conjugates and methods of producing same
DE602005000938T2 (en) * 2004-02-17 2008-01-17 Tyco Healthcare Group Lp, Norwalk Surgical stapler with locking mechanism
US7807804B2 (en) 2004-10-05 2010-10-05 Wyeth Llc Methods and compositions for improving recombinant protein production
WO2006047670A2 (en) 2004-10-26 2006-05-04 Wyeth Methods for assessing antibodies to neurodegenerative disease-associated antigens
ES2434732T3 (en) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Humanized beta-amyloid antibodies for use in improving cognition
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
WO2006066233A1 (en) 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
ES2396555T3 (en) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Antibodies that recognize beta amyloid peptide
PA8661401A1 (en) 2005-01-28 2006-09-08 Wyeth Corp FORMULATIONS OF THE STABILIZED POLYPEPTIDE LIQUID
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
BRPI0611599A2 (en) 2005-06-17 2011-02-22 Elan Pharma Int Ltd method for purifying a beta-binding protein and beta-binding protein
AU2008242648B2 (en) 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE

Also Published As

Publication number Publication date
JP2008528612A (en) 2008-07-31
WO2006083689A3 (en) 2006-10-19
CN103768009A (en) 2014-05-07
AU2006211184A1 (en) 2006-08-10
AU2006211184B2 (en) 2011-06-16
CN103768009B (en) 2016-02-24
UA87549C2 (en) 2009-07-27
HK1196570A1 (en) 2014-12-19
IL184599A0 (en) 2007-10-31
CA2593122A1 (en) 2006-08-10
AR052198A1 (en) 2007-03-07
JO2740B1 (en) 2014-03-15
EP2392353A1 (en) 2011-12-07
HK1118723A1 (en) 2009-02-20
EP1853310A2 (en) 2007-11-14
US20100166752A1 (en) 2010-07-01
UY29351A1 (en) 2006-08-31
DK1853310T3 (en) 2012-10-22
JP4977625B2 (en) 2012-07-18
AU2006211184B8 (en) 2011-07-07
CN101262884A (en) 2008-09-10
MY177052A (en) 2020-09-03
ES2391407T3 (en) 2012-11-26
PT1853310E (en) 2012-10-22
CN101262884B (en) 2012-10-31
KR101188060B1 (en) 2012-10-24
CA2593122C (en) 2012-03-06
DOP2006000021A (en) 2006-08-15
HK1108132A1 (en) 2008-05-02
US8318164B2 (en) 2012-11-27
EA200701596A1 (en) 2008-02-28
KR20070108193A (en) 2007-11-08
PE20060879A1 (en) 2006-08-19
EA201100180A1 (en) 2011-10-31
NZ556393A (en) 2010-02-26
US7635473B2 (en) 2009-12-22
NO20073305L (en) 2007-08-24
TWI398263B (en) 2013-06-11
ZA200705710B (en) 2008-10-29
US20060193850A1 (en) 2006-08-31
WO2006083689A2 (en) 2006-08-10
EA015147B1 (en) 2011-06-30
TW200700080A (en) 2007-01-01
IL184599A (en) 2011-08-31
GT200600031A (en) 2006-08-29
PL1853310T3 (en) 2012-12-31
EP1853310B1 (en) 2012-08-01
BRPI0607039A2 (en) 2009-08-25
EA021507B1 (en) 2015-07-30
SI1853310T1 (en) 2012-11-30

Similar Documents

Publication Publication Date Title
MX2007009050A (en) Anti a beta antibody formulation.
TW200638943A (en) Stabilized liquid polypeptide formulations
MX2008013508A (en) Antagonist anti-cd40 antibody pharmaceutical compositions.
CY1121420T1 (en) STABILIZED PREPARATIONS CONTAINING ANTIBODIES ON THE INTERLEUKIN-6 RECEPTOR (IL-6R)
EA201270625A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
HK1088840A1 (en) Stable analogs of glp-1 glp-1
BRPI0809366B8 (en) substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition
MX336807B (en) Compositions and methods for producing a composition.
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
MX2007005521A (en) Stable formulations of insulinoptropic peptides.
WO2010009277A3 (en) Immunogenic amphipathic peptide compositions
AR113422A2 (en) RECONSTITUTED SURFACTIVE AGENTS HAVING IMPROVED PROPERTIES
UY32279A (en) STABLE COMPOSITIONS OF ANTIBODIES AND METHODS TO STABILIZE THEM
AR076973A1 (en) IMPROVED RECONSTITUTED TENSIOACTIVE COMPOSITION CONTAINING ANALOGS OF THE TENSIOACTIVE PROTEIN B (SP-B) AND THE TENSIOACTIVE PROTEIN C (SP-C)
BRPI0815395A2 (en) COMPOSITION, VECTOR, PRODUCT, PHARMACEUTICAL FORMULATION, IN VITRO METHOD TO DETERMINE IF T-CELLS RECOGNIZE A POLYPEPTIDE, AND IN VITRO METHOD TO DETERMINE IF AN INDIVIDUAL IS OR IS AT RISK.
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
ATE539089T1 (en) CYCLIC RECEPTOR-ASSOCIATED PROTEINS (RAP) PEPTIDES
WO2006046978A3 (en) Cationic peptide-mediated transformation
AR075933A1 (en) POLYPEPTIDE AND IMMUNIZATION COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE
WO2008144019A3 (en) Suppression of allergic inflammation by ascaris heme-binding protein (hbp)
MY168207A (en) Fviii-derived peptides
WO2005118786A3 (en) Splice variants of peptide yy, neuropeptide y, pancreatic peptide y and amylin, and uses thereof
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
WO2006047514A3 (en) Daph analogs and inhibition of protein aggregation
CY1113593T1 (en) IL-1 antagonist preparations

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status